Table.

Inclusion and Exclusion Criteria

Inclusion criteria

1. Age ≥20 years old at PCI

2. Undergoing PCI for ACS or stable CAD

3. LDL-C ≥70 mg/dL on daily 10-mg rosuvastatin

4. Fibroatheroma detected on NIRS-IVUS (maxLCBI(4 mm) >100) in non-culprit

5. Angiographically intermediate lesions with diameter stenosis 25–75%

6. Agreement to be enrolled in the trial and signed written informed consent

Exclusion criteria

1. Previous treatment with at least 1 dose of any anti-PCSK9 monoclonal antibody

2. Uncontrolled hypertension (SBP >180 mmHg or DBP >110 mmHg) between the time of PCI and randomization visit

3. Known hypersensitivity to alirocumab or rosuvastatin

4. All contraindications to alirocumab and/or rosuvastatin as displayed in the respective national product labeling for these treatments

5. Known history of hemorrhagic stroke

6. Current treatment for cancer

7. Current lipoprotein apheresis

8. Severe liver or renal dysfunction

9. Pregnancy or breast-feeding

10. Recognition as inadequate by the attending physician

ACS, acute coronary syndrome; CAD, coronary artery disease; DBP, diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol; maxLCBI, maximum lipid core burden index; NIRS-IVUS, near-infrared spectroscopy-intravascular ultrasound; PCI, percutaneous coronary intervention; PCSK9, proprotein convertase subtilisin/kexin type 9; SBP, systolic blood pressure.